ENCORAFENIB , CETUXIMAB
VHIO23004
Phase 2 small_molecule active
Quick answer
ENCORAFENIB , CETUXIMAB for Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment. is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active